[go: up one dir, main page]

WO2002059350A3 - Use of sialyltransferases for diagnosing and treating tumorous diseases - Google Patents

Use of sialyltransferases for diagnosing and treating tumorous diseases Download PDF

Info

Publication number
WO2002059350A3
WO2002059350A3 PCT/DE2002/000263 DE0200263W WO02059350A3 WO 2002059350 A3 WO2002059350 A3 WO 2002059350A3 DE 0200263 W DE0200263 W DE 0200263W WO 02059350 A3 WO02059350 A3 WO 02059350A3
Authority
WO
WIPO (PCT)
Prior art keywords
st6galnac
expression
sialyltransferases
diagnosing
sialyltransferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE2002/000263
Other languages
German (de)
French (fr)
Other versions
WO2002059350A2 (en
Inventor
Frank Schneider
Wolfgang Kemmner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of WO2002059350A2 publication Critical patent/WO2002059350A2/en
Publication of WO2002059350A3 publication Critical patent/WO2002059350A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to the use of sialyltransferases, in particular of sialyltransferase ST6GalNAc-II for diagnosing and treating tumorous diseases. The mRNA expression of the sialyltransferase enzyme ST6GalNAc-II increases in cases where lymph node metastases occur. Research into 40 well-documented cases of colorectal carcinomas show that the expression of ST6GalNAc-II constitutes a prognostic factor for the survival of such patients. In addition, by blocking the expression of sialyltransferase ST6GalNAc-II, the synthesis of the tumour-linked antigen TF can be blocked, potentially improving the prognosis. The invention also relates to the inhibition of the expression of the enzyme by pharmaceutical agents.
PCT/DE2002/000263 2001-01-26 2002-01-25 Use of sialyltransferases for diagnosing and treating tumorous diseases Ceased WO2002059350A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2001103695 DE10103695A1 (en) 2001-01-26 2001-01-26 Use of sialyltransferases for the diagnosis and therapy of tumor diseases
DE10103695.7 2001-01-26

Publications (2)

Publication Number Publication Date
WO2002059350A2 WO2002059350A2 (en) 2002-08-01
WO2002059350A3 true WO2002059350A3 (en) 2003-06-05

Family

ID=7671950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/000263 Ceased WO2002059350A2 (en) 2001-01-26 2002-01-25 Use of sialyltransferases for diagnosing and treating tumorous diseases

Country Status (2)

Country Link
DE (1) DE10103695A1 (en)
WO (1) WO2002059350A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2048242A1 (en) * 2007-10-08 2009-04-15 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Microarray for expression analysis of cellular glycosylation

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BIOCHEMISTRY, vol. 38, no. 27, 6 July 1999 (1999-07-06), pages 8762 - 8769, ISSN: 0006-2960 *
COLLER H A ET AL: "Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 28 MAR 2000, vol. 97, no. 7, 28 March 2000 (2000-03-28), pages 3260 - 3265, XP002185706, ISSN: 0027-8424 *
DALL'OLIO FABIO ET AL: "Differential expression of the hepatic transcript of beta-galactoside alpha2,6-sialyltransferase in human colon cancer cell lines.", INTERNATIONAL JOURNAL OF CANCER, vol. 81, no. 2, 12 April 1999 (1999-04-12), pages 243 - 247, XP002232476, ISSN: 0020-7136 *
DAO T L ET AL: "SERUM AND TUMOR SIALYLTRANSFERASE ACTIVITIES IN WOMEN WITH BREAST CANCER", PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH, 1986, pages 31 - 44, XP009006191, ISSN: 0361-7742 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 6 July 1999 (1999-07-06), ZENG GUICHAO ET AL: "Alteration of ganglioside composition by stable transfection with antisense vectors against GD3-synthase gene expression.", XP002232496, Database accession no. PREV199900356557 *
DE A K ET AL: "ELUCIDATION OF SIALYLTRANSFERASE AS A TUMOR MARKER", INDIAN JOURNAL OF BIOCHEMISTRY AND BIOPHYSICS, vol. 27, no. 6, 1990, pages 452 - 455, XP009006226, ISSN: 0301-1208 *
GANGOPADHYAY ANIRUDDHA ET AL: "Differential expression of alpha2,6-sialyltransferase in colon tumors recognized by a monoclonal antibody.", HYBRIDOMA, vol. 17, no. 2, April 1998 (1998-04-01), pages 117 - 123, XP009006198, ISSN: 0272-457X *
ITOH H ET AL: "Expression of fucosyltransferases and sialyltransferases in human colorectal cancer.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 37, 1996, 87th Annual Meeting of the American Association for Cancer Research;Washington, D.C., USA; April 20-24, 1996, 1996, pages 63 - 64, XP001146009, ISSN: 0197-016X *
KEMMNER W ET AL: "Different sialyltransferase activities in human colorectal carcinoma cells from surgical specimens detected by specific glycoprotein and glycolipid acceptors.", CLINICAL & EXPERIMENTAL METASTASIS, vol. 12, no. 3, 1994, pages 245 - 254, XP009006194, ISSN: 0262-0898 *
KEMMNER W ET AL: "Expression of sialyltransferase ST6GalNAc II is an independent prognostic marker for colorectal carcinomas.", CLINICAL & EXPERIMENTAL METASTASIS, vol. 17, no. 9, 1999, VIII International Congress of the Metastasis Research Society;London, UK; September 24-27, 2000, pages 785, XP009006195, ISSN: 0262-0898 *
KEMMNER W ET AL: "Inhibition of Gal beta1, 4GlcNAc alpha2,6 sialyltransferase expression by antisense-oligodeoxynucleotides.", FEBS LETTERS. NETHERLANDS 16 JUN 1997, vol. 409, no. 3, 16 June 1997 (1997-06-16), pages 347 - 350, XP002232472, ISSN: 0014-5793 *
LIN SHAOQIANG ET AL: "Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells.", EXPERIMENTAL CELL RESEARCH. UNITED STATES 15 MAY 2002, vol. 276, no. 1, 15 May 2002 (2002-05-15), pages 101 - 110, XP002232474, ISSN: 0014-4827 *
LISE M ET AL: "Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), 90th Annual Meeting of the American Association for Cancer Research;Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999, pages 340, XP001145499, ISSN: 0197-016X *
LISE MARIO ET AL: "Clinical correlations of alpha2,6-sialyltransferase expression in colorectal cancer patients.", HYBRIDOMA, vol. 19, no. 4, August 2000 (2000-08-01), pages 281 - 286, XP009006197, ISSN: 0272-457X *
ORLACCHIO A ET AL: "Activity levels of a beta1,6 N-acetylglucosaminyltransferase in lymphomonocytes from multiple sclerosis patients.", JOURNAL OF THE NEUROLOGICAL SCIENCES. NETHERLANDS 22 OCT 1997, vol. 151, no. 2, 22 October 1997 (1997-10-22), pages 177 - 183, XP002232475, ISSN: 0022-510X *
RECCHI MARIE-ANGE ET AL: "Multiplex RT-PCR method for the analysis of the expression of human sialyltransferases: Application to breast cancer cells.", GLYCOCONJUGATE JOURNAL, vol. 15, no. 1, January 1998 (1998-01-01), pages 19 - 27, XP009006224, ISSN: 0282-0080 *
SCHNEIDER F ET AL: "Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas.", CANCER RESEARCH. UNITED STATES 1 JUN 2001, vol. 61, no. 11, 1 June 2001 (2001-06-01), pages 4605 - 4611, XP002232470, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2002059350A2 (en) 2002-08-01
DE10103695A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
NO970039L (en) Method of inhibiting cancer metastases by oral administration of soluble modified citrus pectin
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2003037060A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2000018795A3 (en) Compositions and methods for wt1 specific immunotherapy
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
WO2000004954A3 (en) Novel urokinase inhibitors
WO2002044360A3 (en) Modified arginine deiminase
WO2001024684A3 (en) Methods for treatment of solid tumors and metastasis by gene therapy
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
AU2002313426A1 (en) Tumor antigens for prevention and/or treatment of cancer
WO2002059350A3 (en) Use of sialyltransferases for diagnosing and treating tumorous diseases
WO2000029012A8 (en) Methods of alleviating cancer symptoms
ATE245163T1 (en) VACCINE AGAINST METASTASIC COLORECTAL CANCER.
WO2002020000A3 (en) Combined estrogen blockade of the breast with exemestane and raloxifene
AU1774299A (en) Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
HUP0300772A3 (en) Medicament for the immunotherapy of malignant tumours
AU1700700A (en) Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
WO2004028541A3 (en) Composition for the treatment of nasopharyngeal carcinoma and use thereof
EP1686122A4 (en) Antitumor agent
AU2003236701A1 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
AU5802200A (en) Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors
WO2003035104A3 (en) Compositions and methods for selected tumor treatment
AU2002254524A1 (en) Use of semenogelin in the diagnosis, prognosis and treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase